Leonardo Macias, MD
Cardiovascular Disease · Albuquerque, NMNPI 1710154315
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Novartis at 57.8% of the total. Reporting peaked in 2019 at $8,833 and has fallen 91.3% since, to $769 in 2025. Among cardiovascular disease clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $76.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- Abbott$2K
- Abiomed$1K
- Boston Scientific$556
- Heartflow, Inc.$493
- AstraZeneca$352
- plus $1K from 12 others
Across 23 payments — averaging $9534.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$93K
- Novartis$69K
- Amgen$57K
What the payments were for
- Speaking & faculty fees$7,34050%
- Travel & lodging$1,3429%
- Food & beverage$5,90540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 74 | $8,438 |
| Abbott | 23 | $2,091 |
| Abiomed | 18 | $1,430 |
| Boston Scientific | 20 | $556 |
| Heartflow, Inc. | 5 | $493 |
| AstraZeneca | 8 | $352 |
| E.r. Squibb & Sons, L.L.C. | 11 | $310 |
| Cvrx, Inc. | 6 | $266 |
| Amgen | 11 | $194 |
| Edwards Lifesciences | 1 | $140 |
| Medtronic(2 entities) | 3 | $93 |
| Boehringer Ingelheim | 1 | $46 |
| Pfizer | 2 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $37 |
| GE HealthCare | 1 | $36 |
| Siemens Medical Solutions USA, Inc. | 1 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$7,562
- Impella$1,110
- FFRct$311
- MitraClip$224
- PASCAL$140
- LOKELMA$134
- Mitra Clip system$127
- WATCHMAN Access System$121
- Barostim Neo System$120
- HeartMate 3 Left Ventricular Assist Device$116
- CAMZYOS$114
- LEQVIO$109
- HeartMate 3 Left Ventricular Dev$102
How this compares
$14,586 in reported general payments places this provider in the 95th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 23 | $577,350 |
| XareltoRivaroxaban | 204 | $243,548 |
| EntrestoSacubitril/Valsartan | 211 | $236,944 |
| EliquisApixaban | 76 | $86,557 |
| FarxigaDapagliflozin Propanediol | 77 | $75,618 |
| Repatha SureclickEvolocumab | 67 | $43,906 |
| Metoprolol Succinate | 393 | $7,234 |
| Atorvastatin Calcium | 384 | $5,494 |
| Spironolactone | 209 | $2,598 |
| Carvedilol | 212 | $2,593 |
| Losartan Potassium | 172 | $2,542 |
| Bumetanide | 63 | $2,397 |
| Furosemide | 244 | $2,334 |
| Rosuvastatin Calcium | 99 | $2,057 |
| Potassium Chloride | 74 | $2,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $40 | $663,90799 claims |
| Johnson & JohnsonXarelto | $15 | $243,548204 claims |
| NovartisEntresto | $8,438 | $236,944211 claims |
| AstraZenecaFarxiga | $352 | $75,61877 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Albuquerque
- Abinash AchrekarAlbuquerque$88K
- Adam BanksAlbuquerque$38K
- Stacey CleggAlbuquerque$21K
- Carolina Ponce OrellanaAlbuquerque$12K
- Phillip CampAlbuquerque$11K
- Warren LaskeyAlbuquerque$10K
- Kayvan ElliniAlbuquerque$10K
- Bilal AlqamAlbuquerque$8K
- Daniel FriedmanAlbuquerque$6K
- Robert TaylorAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.